TY  - GEN
AU  - McCracken,D Jay
AU  - Celano,Emma C
AU  - Voloschin,Alfredo D
AU  - Read,William L
AU  - Olson,Jeffrey J
TI  - Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma
SN  - 1573-7373
PY  - 2018///0101
KW  - Adult
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - Bortezomib
KW  - Brain Neoplasms
KW  - drug therapy
KW  - Dacarbazine
KW  - analogs & derivatives
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Female
KW  - Follow-Up Studies
KW  - Glioblastoma
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Temozolomide
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1007/s11060-016-2234-6
ER  -